AnaptysBio Inc. (ANAB)

76.57 +0.09 (+0.118%)

IEX Real-Time Price

June 20, 2018 EST.

Nasdaq Global Select : Healthcare

Prev Close 76.48

Price Open 77.18

Volume: 214,239

Avg Volume: 363,761

Market Cap: 1.8B

P/E Ratio -50.71

52 Wk Range 20.12-134



ANAB Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-05-31
23.16M
2.05M
6.51
8.84%

2018-05-15
23.12M
2.51M
9.03
10.86%

2018-04-30
23.12M
2.6M
6.27
11.23%

2018-04-13
23.43M
2.52M
4.28
10.73%




ANAB Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-10
Q1 2018
N/A
-0.44 (4)
0.00
0.00

2018-05-08
Q1 2018
N/A
-0.44 (4)
-0.63
-0.19

2018-03-06
Q4 2017
N/A
-0.41 (5)
0.00
0.00

2018-03-05
Q4 2017
N/A
-0.41 (5)
-0.30
0.11

News

Institutional Top Ideas: Cormorant Asset Management (2018-06-16 18:41 SeekingAlpha)

In the last entry of this series we took a look at top ideas from EcoR1 Capital, a hedge fund with high returns and a higher percentage of the portfolio in its top 10 holdings (making it a good one to keep tabs on). The series is down to its last two funds to be reviewed, as usual trying t…

 


Statistics

Shares Outstanding: 23.5M

Top 15 Institution Percent: 92.00

Price To Sales: 189.74

Price To Book: 6.44

Revenue: 7.00M

Gross Profit: N/A

Cash: 222.08M

Debt: 28.38M

Return On Assets: -14.46

Return On Equity: -15.98

Profit Margin: N/A

Price History

Beta: 2.77

50-day Moving Avg: 84.88

200-day Moving Avg: 84.51

YTD Change: -23.96

5-day Change: 8.42

1-month Change: -12.04

3-month Change: -30.10

6-month Change: -16.87

1-year Change: N/A

Revenue Per Share: 0.00

Revenue Per Employee: 116667.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: AnaptysBio Inc.

Exchange: Nasdaq Global Select

Industry: Biotechnology

Sector: Healthcare

Website: http://www.anaptysbio.com

AnaptysBio Inc is a biotechnology company. The company is engaged in developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. Its product include ANB020 and ANB019.